Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma
Université de Montpellier · Institut Gustave Roussy · +18 more institutions
Abstract
Erdafitinib is a pan–fibroblast growth factor receptor (FGFR) inhibitor approved for the treatment of locally advanced or metastatic urothelial carcinoma in adults with susceptible FGFR3/2 alterations who have progression after platinum-containing chemotherapy. The effects of erdafitinib in patients with FGFR-altered metastatic urothelial carcinoma who have progression during or after treatment with checkpoint inhibitors (anti–programmed cell death protein 1 [PD-1] or anti–programmed death ligand 1 [PD-L1] agents) are unclear. Download a PDF of the Research Summary. We conducted a global phase 3 trial of erdafitinib as compared with chemotherapy in patients with metastatic urothelial carcinoma with susceptible…
Citation impact
- FWCI
- 84.06
- Percentile
- 100%
- References
- 15
Authors
18- YLYohann LoriotCorresponding
Université de Montpellier, Institut Gustave Roussy, Goethe University Frankfurt, Inserm, Université Paris-Saclay
- NMNobuaki Matsubara
Goethe University Frankfurt, Université Paris-Saclay, National Cancer Center Hospital East, Institut Gustave Roussy, Inserm, Université de Montpellier
- SHSe Hoon Park
Université Paris-Saclay, Goethe University Frankfurt, Samsung Medical Center, Université de Montpellier, Inserm, Sungkyunkwan University, Institut Gustave Roussy
- RHRobert Huddart
Royal Marsden NHS Foundation Trust, Institut Gustave Roussy, Université de Montpellier, Goethe University Frankfurt, Institute of Cancer Research, Inserm, Université Paris-Saclay
- EFEarle F. Burgess
Inserm, Institut Gustave Roussy, Levine Cancer Institute, Goethe University Frankfurt, Université Paris-Saclay, Université de Montpellier
Topics & keywords
- Urothelial carcinoma
- Metastatic Urothelial Carcinoma
- Chemotherapy
- Medicine
- Oncology
- Carcinoma
- Urology
- Internal medicine
- Good health and well-being